Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, India.
Maliba Pharmacy College, Uka Tarsadia University, Tarsadi, India.
J Microencapsul. 2022 Jan;39(1):1-24. doi: 10.1080/02652048.2021.2002448. Epub 2021 Dec 6.
In the current study, efforts are being made to prepare Inhalable Silibinin loaded solid lipid nanoparticles (SLNs) with narrow size distribution with improved bioavailability.
SLNs were formulated by high shear homogenisation method SLNs were characterised, including Differential Scanning Calorimetry (DSC), Fourier transform infra-red spectroscopy (FTIR), particle size analysis, entrapment efficiency with Aerodynamic behaviour. The MTT assay was performed against A549 cell line, to measure their anticancer cell activity with study.
Optimized formulation exhibited spherical surface with a mean particle size of 221±1.251nm, PI of 0.121± 0.081, zeta potential of -4.12±0.744. Aerodynamic behaviour such as Mass median aerodynamic diameter (MMAD) and Geometric size distribution (GSD) were found to be 5.487 ± 0.072 and 2.321 ± 0.141 respectively proved formulation is suitable for inhalation. cellular efficacy against A549 cells, revealed that the optimised formulations were more effective and potent.
The Inhalable SLNs approach was successfully engineered and administered to the lungs safely without causing any problems.
在目前的研究中,努力制备具有窄粒径分布和提高生物利用度的可吸入水飞蓟宾负载固体脂质纳米粒(SLN)。
采用高剪切匀化法制备 SLN,对其进行差示扫描量热法(DSC)、傅里叶变换红外光谱(FTIR)、粒径分析、包封效率和空气动力学行为进行表征。采用 MTT 法对 A549 细胞系进行测定,以评估其抗癌细胞活性。
优化的配方显示出具有平均粒径为 221±1.251nm、PI 为 0.121±0.081、zeta 电位为-4.12±0.744 的球形表面。空气动力学行为如质量中值空气动力学直径(MMAD)和几何粒径分布(GSD)分别为 5.487±0.072 和 2.321±0.141,表明该配方适合吸入。对 A549 细胞的细胞功效表明,优化的配方更有效和有效。
成功地设计并将可吸入 SLN 递送到肺部,而不会引起任何问题。